The management of respiratory failure during acute exacerbations of COPD and during chronic stable COPD is reviewed and the role of non-invasive and invasive mechanical ventilation is discussed.

**MANAGEMENT OF RESPIRATORY FAILURE DURING ACUTE EXACERBATIONS OF COPD**

The purpose of managing respiratory failure/supporting ventilation in acute exacerbations of chronic obstructive pulmonary disease (COPD) is to prevent tissue hypoxia and control acidosis and hypercapnia while medical treatment works to maximise lung function and reverse the precipitating cause of the exacerbation. There are four strategies to consider:

- **oxygen therapy**;
- **respiratory stimulants**;
- **non-invasive ventilation**; and
- **invasive mechanical ventilation**.

They should be considered as adjuncts to optimum medical treatment which will usually include bronchodilators, systemic steroids, and antibiotics. Their use will depend on availability, but also on the severity of the respiratory failure.

**pH as a marker of severity**

In acute exacerbations of COPD, pH is the best marker of severity and reflects an acute deterioration in alveolar hypoventilation compared with the chronic stable state. Regardless of the chronic level of arterial carbon dioxide tension (Paco2), an acute rise in Paco2 due to worsening alveolar hypoventilation is associated with a fall in pH. Warren et al. retrospectively reviewed 157 admissions with COPD and found that death was associated with increasing age and a low pH, a pH of <7.26 being associated with a particularly poor prognosis. In 1992 this group also reported a prospective study of 139 episodes of respiratory failure in 95 patients with COPD. Death occurred in 10 of the 39 episodes in which pH rose above 55 mmol/l (that is, pH <7.26). Hypoxia and hypercapnia were not different between the survivors and those who died. Similarly, in a 1 year period prevalence study of patients admitted to hospital with COPD, the mortality in patients with a normal pH was 6.9%, rising to 13.8% in those who were acidic (pH <7.35) after initial medical treatment. Moreover, studies of non-invasive ventilation (NIV) have also found pH to be predictive of the need for intubation and inhospital mortality. These data support the theoretical view that it is not the absolute level of Paco2 that is important but the magnitude and speed of any change, which is reflected by pH. COPD patients with acidosis account for 20% of all COPD admissions.

**Oxygen therapy**

Since the 1960s it has been known that uncontrolled oxygen therapy can produce respiratory acidosis and CO2 narcosis, requiring invasive mechanical ventilation. Similarly, there is concern that leaving patients profoundly hypoxic is potentially life threatening—for example, due to arrhythmia. The mechanism by which oxygen is responsible for the deterioration in arterial blood gases is ill understood. However, the main mechanism appears to be an increase in Vd/Vt with a small component due to a reduction in respiratory drive. At present the BTS guidelines recommend that PaO2 should be maintained at >.6 kPa without a fall in pH below 7.26, or >7.5 kPa if the pH is satisfactory. Controlled oxygen therapy is recommended—that is, fixed percentage Venturi masks or low flow nasal cannulae. The latter are associated with more variable Fio2. However, there are no good quality data on the proportion of patients at risk because these studies are very difficult to perform. Studies in patients with stable COPD are unlikely to be generalisable to the unstable state, so acute studies are necessary. There are some epidemiological data to suggest that all hypercapnic patients are susceptible to oxygen therapy and these account for 47% of COPD admissions. There is also some evidence that maintaining SpO2 between 85% and 92% (equivalent to 7.3–10 kPa) minimises the risk of acidosis and that a PaO2 of >10 kPa is associated with acidosis in 33–50% of hypercapnic COPD patients. Jubran and Tobin studied invasively ventilated patients and found that targeting an SpO2 of 92% provided a satisfactory level of oxygenation, but that oximetry was less reliable in black patients. Taking into account the shape of the oxygen dissociation curve and that patients with COPD are usually acclimatised to a degree of hypoxia, delivering oxygen to maintain an SpO2 of 85–92% may be safer and more appropriate than recommending a particular concentration of oxygen. In a small study Moloney et al found that only three of 24 patients developed clinically important CO2 retention (defined as a rise in Paco2 of >1 kPa) with oxygen therapy administered to maintain the oxygen saturation at 91–92%. However, Agusti et al found that delivering oxygen at the lowest concentration to achieve an SpO2 >90% was associated with significant periods during
the 24 hours when SpO₂ was <90%, but that this was less with
Venturi masks than with nasal cannulae (5.4 v 3.7 hours, p<0.05). However, there were no episodes of worsening hypercapnia or acidosis in the patients under study. There are no definitive data to inform the correct use of supplemental oxygen in acute exacerbations of COPD, but individual titration with regular monitoring of pulse oximetry and arterial blood gas tensions should be performed. There is evidence that oxygen therapy is more effective with the use of a prescription chart.25

Respiratory stimulants
Doxapram is the most widely used respiratory stimulant. Its effectiveness has been the subject of a Cochrane systematic review,26 the conclusions of which were that doxapram is the most effective respiratory stimulant but is only able to provide minor short term improvement in blood gas tensions.27-29 One randomised controlled trial has compared the effectiveness of doxapram with NIV.30 Seventeen patients were randomised to receive either NIV (n=9) or conventional therapy plus doxapram (n=8). In the doxapram group an improvement in Pao₂ was seen at 1 hour compared with baseline, but by 4 hours no difference was seen in either Pao₂ or Paco₂. In the NIV group Pao₂ and Paco₂ improved and was maintained. There was a statistically non-significant trend to improved survival in the NIV group with 3/8 surviving with conventional care and 9/9 surviving with NIV. With the increasing use of NIV, doxapram should be confined to patients who are awaiting intubation of NIV, when it is not available or poorly tolerated, or for those who have reduced drive—for example, due to sedatives and anaesthetic agents.

Non-invasive ventilation
NIV can be used in the intensive care unit, in the ward, or in the accident and emergency department. A number of randomised controlled trials have looked at the effectiveness of NIV in these locations (table 1), with most including patients with an acute exacerbation of COPD, a raised respiratory rate, and a pH <7.35 with a PaCO₂ of >6 kPa.31-33 Patients deemed to warrant immediate intubation were excluded from all studies.

The rates of intubation and mortality are generally higher in the ICU studies despite similar arterial blood gas criteria.34-36 Patients in the emergency department who are acidic will have had little time to respond to medical treatment and hence those allocated to medical treatment will generally do well, avoiding intubation and mortality.37 By comparison, individuals in the ICU remain acidic despite much medical treatment and, for them, being allocated to medical treatment will be associated with a higher risk of intubation or mortality. By pooling the ICU studies (mean pH 7.28), the risk of intubation is 38% (95% CI 29-49%) with a 66% reduction in risk with NIV to 21% (±7.7%).32-36 Similarly, NIV reduces mortality from 25% (±8.4%) to 9% (±5.6%), a risk reduction of 64%. Hence, in the ICU the numbers needed to treat (NNT) are 2.4 to prevent one intubation and 6.3 to prevent one death. In health economic terms Keenan et al38 have also shown, using decision tree analysis, that NIV in the ICU results in improved clinical outcomes but also reduced costs from the hospital’s perspective.

In the ward setting 16% of all patients admitted with COPD remain acidotic.39 For a typical district general hospital, this equates to 72 patients per year.40 It is not possible in the UK for all these patients to be managed on the ICU and ward based NIV has to be considered. However, the technique is likely to be less effective in this setting with a lower nurse to patient ratio, limited monitoring facilities, and less experience of ventilatory support.

In the largest ward trial, simple protocol driven NIV reduced the need for intubation on objective criteria from 27% to 11%, real intubation rates from 11% to 6%, and mortality from 20% to 10%. A risk reduction for all three end points of 45–50% and NNT of 8.4% to 9% (±7.4%).39,41 Similarly, NIV reduces mortality from 25% (±8.4%) to 9% (±5.6%), a risk reduction of 64%. Hence, in the ICU the numbers needed to treat (NNT) are 2.4 to prevent one intubation and 6.3 to prevent one death. In health economic terms Keenan et al38 have also shown, using decision tree analysis, that NIV in the ICU results in improved clinical outcomes but also reduced costs from the hospital's perspective.

Within the A&E there is little evidence to support the routine use of NIV in all acidic patients as the study by Barbe et al showed that no patients in the conventional arm required endotracheal intubation or died.42 Moreover, it is known that 20% of all acidic patients in the A&E correct their pH by the time they reach the ward, and the study by Barbe et al with only 12 patients in each limb was underpowered to pick up a difference in outcome.42

Monitoring of patients on NIV and managing the failing patient
One study in the ward environment has shown a potential disadvantage of NIV. Wood et al43 randomised 27 patients with acute respiratory distress to receive conventional treatment or NIV in the emergency department. Intubation rates were similar (7/16 v 5/11), but there was a non-significant trend

---

**Table 1** Effectiveness of non-invasive ventilation (NIV) in patients with COPD in the ICU, on the ward, and in A&E departments

<table>
<thead>
<tr>
<th>Setting</th>
<th>Baseline data pH</th>
<th>Eti or &quot;surrogate&quot;</th>
<th>Mortality</th>
<th>Mode plus settings (cm H₂O) and use on day 1 (when stated)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brochard et al44</td>
<td>ICU</td>
<td>7.28 v 7.27</td>
<td>Eti v &quot;surrogate&quot;</td>
<td>4/43 v 12/42 PSV 20 for at least 6 hours/day</td>
</tr>
<tr>
<td>Celikel et al45</td>
<td>ICU</td>
<td>7.27 v 7.28</td>
<td>1/15 v 2/15</td>
<td>0/15 v 1/15 PSV 15.4 for mean of 26.7 hours</td>
</tr>
<tr>
<td>Kramer et al46</td>
<td>ICU</td>
<td>7.29 v 7.27</td>
<td>9/9 v 6/7</td>
<td>IPAP 11.3, EPAP 2 6 for 20.1 hours</td>
</tr>
<tr>
<td>Martin et al47</td>
<td>ICU</td>
<td>7.27 v 7.28</td>
<td>5.26 v</td>
<td>IPAP 5.7</td>
</tr>
<tr>
<td>Ward studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Angus et al48</td>
<td>Ward</td>
<td>7.31 v 7.30</td>
<td>0/9 v 5/8</td>
<td>0/9 v 3/8 IPAP 14-18</td>
</tr>
<tr>
<td>Barbi et al49</td>
<td>Ward</td>
<td>7.34 v 7.39</td>
<td>1/15 v 2/15</td>
<td>0/15 v 1/15 IPAP 13, EPAP 3</td>
</tr>
<tr>
<td>Bardi et al50</td>
<td>Ward</td>
<td>7.35 v 7.35</td>
<td>3/30 v 9/30</td>
<td>IPAP 10-20, EPAP 5 for median of 8 hours</td>
</tr>
<tr>
<td>Plant et al51</td>
<td>Ward</td>
<td>7.32 v 7.31</td>
<td>15% v 27%</td>
<td>Volume cycled ventilators for 7.63 hours</td>
</tr>
<tr>
<td>A&amp;E studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barbe et al52</td>
<td>A&amp;E and ward</td>
<td>7.33 v 7.33</td>
<td>0/12 v 0/12</td>
<td>See text</td>
</tr>
<tr>
<td>Wood et al53</td>
<td>A&amp;E</td>
<td>7.35 v 7.34</td>
<td>0/12 v 0/12</td>
<td>See text</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>IPAP 14.8, EPAP 5 for 2 x 3 hour sessions per day</td>
</tr>
</tbody>
</table>

Eti=endotracheal intubation; PSV=pressure support ventilation.
Table 2
Controlled clinical trials of non-invasive ventilation (NIV) versus conventional therapy: 1 year survival

<table>
<thead>
<tr>
<th>Study</th>
<th>n</th>
<th>Conventional</th>
<th>NIV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plant</td>
<td>118</td>
<td>54%</td>
<td>62%</td>
</tr>
<tr>
<td>Bardi</td>
<td>15</td>
<td>53%</td>
<td>87%</td>
</tr>
<tr>
<td>Confalonieri</td>
<td>24</td>
<td>50%</td>
<td>71%</td>
</tr>
<tr>
<td>Vitacca</td>
<td>27/30</td>
<td>37%*</td>
<td>70%</td>
</tr>
</tbody>
</table>

*All intubated in the conventional control group.

Towards increased mortality in those given NIV (4/16 v 0/11, p=0.123). The authors attributed the excess mortality to a delay in intubation as conventional patients requiring invasive ventilation were intubated after 4.8 hours compared with 26 hours in those on NIV (p=0.055). It is difficult to draw many conclusions from this study about the place of NIV in acute exacerbations of COPD, given its small size; only six patients had COPD and they were not severely ill on pH criteria (mean pH at entry 7.35). The groups were also poorly matched with more cases of pneumonia in the NIV group. However, it does highlight the need to monitor patients, offer NIV in a location with trained nurses, and to ensure that endotracheal intubation is promptly available when needed.

In assessing the appropriateness for IMV and the associated ICU admission, the severity of the underlying disease, the reversibility of the precipitating cause, the quality of life of the patient, and the presence of severe co-morbidities should be considered. NIV may have a role in patients who have been intubated from the outset or after a failed trial of NIV. Nava et al found that extubation onto NIV after a failed T-piece trial at 48 hours was associated with a shorter duration of ventilatory support (10.2 days v 16.6 days), a shorter ITU stay (15.1 days v 24 days), less nosocomial pneumonia (0/25 v 7/25), and improved 60 day survival (92% v 72%) compared with continued invasive ventilation. However, in a similar study Girault et al did not find any difference in outcome with a similar approach.

Management of respiratory failure in chronic stable COPD

The aim of pharmacological therapy in COPD is to alleviate symptoms by reversing correctable abnormalities, but in many patients the changes are largely irreversible. In time, patients develop respiratory failure, pulmonary hypertension, and peripheral oedema. Once peripheral oedema supervenes, the prognosis is poor with a 5 year mortality of 70–100%. Various therapeutic strategies have been developed to treat the consequences of chronic airway obstruction in an attempt to improve survival and reduce symptoms. These include:

- long term oxygen therapy (LTOT);
- respiratory stimulant drugs; and
- mechanically assisted ventilation.

Long term oxygen therapy (LTOT)

LTOT is one of only two interventions shown to improve survival in patients with COPD, the other being smoking cessation. Two large studies in the 1970s showed at least a doubling in survival when oxygen was used for at least 15 hours per day in patients hypoxaemic due to COPD, although survival improved even further with more daily use. The mechanism by which LTOT improves survival remains unknown. Severity of airflow limitation as measured by FEV1, is a major predictor of survival, and this remains true even in oxygen treated patients. It is currently recommended if the PaO2 falls below 7.3 kPa when the patient is clinically stable, and should be used for at least 15 hours per day. There are no data to support the use of LTOT in patients with predominantly nocturnal hypoxia. In one study patients who did not fulfil the daytime arterial blood gas criteria for LTOT but who did have evidence of nocturnal hypoxia (mean nocturnal SaO2 88%) were randomised to overnight oxygen or standard therapy. They found no difference in survival, evolution of pulmonary hypertension, or the time at which LTOT became necessary.

Drug treatment of chronic ventilatory failure

The use of drugs to improve arterial blood gas tensions has not found widespread acceptance, but a number of drugs have been evaluated, including medroxyprogesterone, acetazolamide, protriptyline, and almitrine bismesylate.

Protriptyline, a non-sedating tricyclic antidepressant, has been shown to improve diurnal blood gas tensions in patients with COPD, increasing PaO2 by approximately 1 kPa. It is thought that the changes are mediated through a reduction in the amount of time spent in rapid eye movement (REM) sleep. Protriptyline has now been withdrawn in the UK, but other non-sedating REM suppressants such as fluoxetine have been shown to have an effect on REM sleep and probably warrant further evaluation. Four short term controlled studies of the use of acetazolamide in patients with chronic COPD have been reported and discussed in a recent Cochrane review. All showed a similar direction and size of effect; acetazolamide caused a metabolic acidosis and produced a non-significant fall in PaCO2 (weighted mean difference (WMD) –0.41 kPa; 95% CI –0.91 to 0.09) and a significant rise in PaO2 (WMD 1.54 kPa; 95% CI 0.97 to 2.11). One study reported an improvement in sleep but there were no data concerning outcomes such as health status, symptoms, exacerbation rate, hospital admissions, or deaths. Side effects were reported infrequently. The reviewers concluded that the drug did have an effect but larger longer term studies were needed. Almitrine bismesylate is a pharmacologically unique respiratory stimulant which has the advantages of oral activity and prolonged duration of action. It has been shown to improve arterial blood gas tensions, particularly PaO2; in one large study PaO2 increased after 1 year by an average of 2.1 kPa in one third of patients and in 55% PaO2...
increased by at least 1.6 kPa compared with placebo. A smaller proportion of patients taking almitrine were admitted to hospital and there were fewer episodes of right heart failure. However, these differences were limited by side effects, particularly peripheral neuropathy,$^{32,34}$ and there is a concern that it may cause worsening pulmonary hypertension,$^{33,35}$ and it is not licensed for use in the UK.

The role of respiratory stimulants probably warrants revisiting as even small changes in Pao2 may result in patients moving above the threshold at which LTOT would be started. It remains to be seen, however, whether this translates into improved survival and patient quality of life.

**Non-invasive ventilation**

A number of studies have shown that NIV is feasible at home during sleep in patients with COPD,$^{12,13}$ and that abnormal physiology can be corrected using NIV. However, there have been few controlled trials and most of these had small numbers of patients followed over a short period of time.$^{14-17}$ They have generally been characterised by no significant advantage from NIV,$^{18-20}$ poor tolerance,$^{21}$ and worse sleep efficiency.$^{22}$ However, Meecham Jones et al.$^{23}$ showed improvements in daytime arterial blood gas tensions, sleep quality, and quality of life during the pressure support (PSV) limb of a crossover study comparing PSV and oxygen with oxygen alone. This was the only study in which the overnight control of nocturnal hyperventilation was confirmed, and the improvement in daytime Pao2, correlated with a reduction in overnight transcutaneous CO2. Possible explanations for the failure of NIV in other studies include: patients not hypercapnic, insufficient insufflation pressures to achieve effective ventilation, and inadequate patient acclimatisation to the technique. Case series of patients with COPD$^{24-26}$ suggest survival comparable to that seen in the oxygen treated patients in the MRC and NOTT studies.$^{27-30}$ These patients were often those who had “failed” (not rigorously defined) despite LTOT.

Preliminary results from two multicentre European trials comparing NIV with LTOT in COPD suggest that NIV does not improve survival but may reduce the need for hospitalisation.$^{31,32}$ Until further data are available, a trial of NIV can only be justified in patients who have symptoms of nocturnal hyperventilation (morning headaches, daytime sleepiness) despite maximal bronchodilator therapy, or cannot tolerate LTOT even with careful administration. It should also be considered in patients with repeated admissions to hospital with acute hypercapnic ventilatory failure. Most studies suggest that it is patients with more severe hypercapnia who are likely to benefit and there is no place for nocturnal NIV at present in those without sustained daytime hypercapnia. Adequate control of nocturnal hyperventilation should be confirmed since this has been a feature of the studies in which benefit has been seen.$^{14-17}$

**CONCLUSIONS**

In acute exacerbations of COPD the purpose of oxygen therapy and ventilatory support is to prevent tissue hypoxia and hypercapnia while medical treatment optimises lung function and reverses the precipitating cause. For most hypercapnic COPD patients, maintaining SpO2 at 85–92% (7.3–10 kPa) with controlled oxygen balances the risks of oxygen induced hypercapnia and tissue hypoxia. A low pH is an indicator of a severe and acute deterioration and such individuals benefit from receiving NIV in a location with trained staff, monitoring, and access to prompt intubation. As this group accounts for 16% of all patients with COPD, this requires ward based provision in the UK which may best be provided in respiratory care units analogous to coronary care units. A proportion of patients will still require IMV, including those who are unconscious on admission and those who fail with NIV in the first few days. NIV should be considered again after 48 hours of IMV. In patients with chronic respiratory failure LTOT remains the gold standard treatment but, in certain highly selected patients, drugs or NIV may have a role; further studies are needed.

**Authors’ affiliations**
P K Plant, M W Elliott, Department of Respiratory Medicine, St James’s University Hospital, Leeds LS9 7TF, UK

**REFERENCES**


www.thoraxjnl.com
Management of ventilatory failure in COPD


Clini E, Shurani C, on behalf of AIPO. The Italian multicentric study of non-invasive nocturnal pressure support ventilation (NPSV) in COPD patients. Am J Respir Crit Care Med 1999;159:A295.


LUNG ALERT

Peroxisome proliferator-activated receptor ligands for airway diseases?


The peroxisome proliferator-activated receptors (PPARs) are ligand-activated nuclear transcription factors belonging to the hormone receptor family. The alpha and gamma subtypes are predominantly expressed in liver, muscle, and adipose tissues where, when activated by ligands such as glitazones, they regulate lipid metabolism. Using RT-PCR, Western blot analysis, and confocal microscopy, Patel and colleagues have shown, for the first time, the expression of these receptors on cultured human airway smooth muscle cells. In addition, activation of the gamma subtype by ciglitazone decreased the synthesis of GM-CSF (an eosinophil survival factor) and G-CSF (a neutrophil survival factor) by stimulated airway smooth muscle cells, demonstrating a potential anti-inflammatory role for this class of drugs in the airway. They also inhibited smooth muscle growth and promoted their apoptosis more potently than dexamethasone.

Since smooth muscle cells have a significant role in airway diseases such as asthma and COPD, PPAR gamma ligands may prove to be effective in regulating their function, particularly in the process of airway remodelling. Their role in regulating airway smooth muscle migration and controlling steroid insensitive airway inflammation needs further study.

K Parameswaran
Firestone Institute for Respiratory Health, St Joseph’s Healthcare and Department of Medicine, McMaster University, Hamilton, Ontario, Canada

parames@mcmaster.ca
Chronic obstructive pulmonary disease • 9: Management of ventilatory failure in COPD

P K Plant and M W Elliott

Thorax 2003 58: 537-542
doi: 10.1136/thorax.58.6.537

Updated information and services can be found at:
http://thorax.bmj.com/content/58/6/537

These include:

References
This article cites 70 articles, 25 of which you can access for free at:
http://thorax.bmj.com/content/58/6/537#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Mechanical ventilation (171)
Mechanical ventilation (158)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/